Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718239 | 0.98 | NAMPT (0.36) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL3402059 | 0.95 | NAMPT (0.38) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL720138 | 0.94 | NPC1 (0.34) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL719320 | 0.92 | NPC1 (0.35) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL10284984 | 0.90 | NAMPT (0.38) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL721576 | 0.89 | NAMPT (0.37) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL718723 | 0.87 | MEN1 (0.44) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL716825 | 0.86 | NPC1 (0.41) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL718999 | 0.86 | NPC1 (0.36) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL718275 | 0.86 | RAB9A (0.40) | NAMPTNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | NAMPT 69/4885NPC1 902/4885RAB9A 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.